Troy Wichterman Sells 956 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 956 shares of BioLife Solutions stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $15.31, for a total transaction of $14,636.36. Following the transaction, the chief financial officer now directly owns 126,658 shares in the company, valued at $1,939,133.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Troy Wichterman also recently made the following trade(s):

• On Thursday, March 21st, Troy Wichterman sold 520 shares of BioLife Solutions stock. The shares were sold at an average price of $17.83, for a total transaction of $9,271.60.
• On Monday, March 11th, Troy Wichterman sold 361 shares of BioLife Solutions stock. The shares were sold at an average price of $17.42, for a total transaction of $6,288.62.
• On Wednesday, February 21st, Troy Wichterman sold 97 shares of BioLife Solutions stock. The shares were sold at an average price of $17.35, for a total transaction of $1,682.95.

BioLife Solutions Trading Up 1.0 %

BLFS opened at $17.19 on Thursday. The stock has a market capitalization of $778.71 million, a P/E ratio of -11.31 and a beta of 1.67. BioLife Solutions, Inc. has a 12 month low of $8.92 and a 12 month high of $24.50. The firm’s fifty day simple moving average is $17.39 and its 200 day simple moving average is $15.41. The company has a current ratio of 2.86, a quick ratio of 1.83 and a debt-to-equity ratio of 0.06.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. The firm had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. As a group, research analysts anticipate that BioLife Solutions, Inc. will post -0.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group began coverage on shares of BioLife Solutions in a research report on Thursday, April 4th. They issued a “buy” rating and a $22.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.40.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its stake in BioLife Solutions by 167.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 1,020 shares during the last quarter. GAMMA Investing LLC acquired a new stake in BioLife Solutions in the 4th quarter valued at $41,000. Register Financial Advisors LLC acquired a new stake in BioLife Solutions in the 1st quarter valued at $96,000. Allspring Global Investments Holdings LLC increased its stake in BioLife Solutions by 88.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 5,324 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of BioLife Solutions by 8.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,622 shares of the medical equipment provider’s stock worth $216,000 after purchasing an additional 1,164 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.